Have Cancer Vaccines Come of Age (or Do They Remain the Unruly Adolescent)?

For more than two decades, cancer vaccines have promised to reshape the oncology landscape—yet their journey has been marked by both breakthroughs and setbacks. Early hopes were tempered by challenges such as the immunosuppressive tumor microenvironment, regulatory hurdles, and the meteoric rise of checkpoint inhibitors. Still, the field has evolved: advances in antigen discovery (from neoantigens to dark antigens), innovative delivery platforms like mRNA, and smarter clinical trial designs have reignited optimism.

In this webinar, we’ll examine the “state of the art” in cancer vaccine development as of 2026—what has worked, what hasn’t, and what’s just over the horizon. Drawing on 20+ years of experience and perspective, our speaker will connect the dots between past failures and current successes, offering a clear view of where this dynamic field is headed, and how science, strategy, and commercial realities intersect to drive new possibilities in immuno-oncology. Our panel will examine:

• Key learnings from two decades of platform, adjuvant, and delivery system development.
• The evolving landscape of personalized vs. off‑the‑shelf cancer vaccines.
• Advances in predicting and identifying the most immunogenic tumor antigens.
• The role of next‑generation RNA technologies in shaping future vaccine development.
• Strategic considerations — scientific, clinical, and commercial — that influence probability of success and value creation.